- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00085384
PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
A Phase I/II Study to Evaluate the Optimum Dose of Pegylated-Interferon (PEG INTRON) in Patients With Platinum Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
RATIONALE: PEG-interferon alfa-2b may interfere with the growth of cancer cells.
PURPOSE: This randomized phase I/II trial is studying the side effects and best dose of PEG-interferon alfa-2b and to see how well it works in treating patients with ovarian epithelial, peritoneal, or fallopian tube cancer that is resistant to platinum-based chemotherapy.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
- Determine the optimum biologic dose of PEG-interferon alfa-2b in patients with platinum-resistant ovarian epithelial, peritoneal, or fallopian tube cancer.
- Determine the safety and tolerability of this drug in these patients.
OUTLINE: This is a randomized study. Patients are randomized to 1 of 3 different treatment arms.
- Arm I: Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
- Arm II: Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
- Arm III: Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
In all arms, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed for at least 28 days after study treatment.
PROJECTED ACCRUAL: A maximum of 75 patients will be accrued for this study within 19 months.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- M D Anderson Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
Women with platinum-resistant epithelial ovarian, fallopian tube or peritoneal cancer whose tumor test positive for IL-8 (>31.0 pg/ml), bFGF >7.0 pg/ml), or VEGF (>700 pg/ml). Resistance is defined as:
- Progression of disease during platinum chemotherapy, or
- Progression of disease within 6 months of completing platinum chemotherapy
- Failure to achieve a complete response, with persistent macroscopic disease, after 6 cycles of chemotherapy, if the last two cycles had no measurable change in disease status
- Patients with a known hypersensitivity to platinum compounds who have failed a desensitization regimen, or who are not good candidates for desensitization are eligible.
- Patients are limited to 4 prior chemotherapy regimens (all platinum and taxane regimens to be counted as one).
- Patients must have measurable disease.
- Women of any racial and ethnic group.
- Zubrod performance status < 2.
- Expected survival of > 12 weeks.
- Patients must have adequate hepatic, renal, and bone marrow function, defined as serum creatinine < 2 mg/dl (estimated creatinine clearance 50 ml/min); total bilirubin < 2.0 X the upper limit of normal (ULN); alanine aminotransferase (ALT) < 2X ULN; fasting triglycerides < 800 mg/dL; white blood count (WBC) > 3,000/mm3 ; absolute neutrophil count (ANC) > 1,500/mm3; platelets > 100,000/mm3, hemoglobin > 9 g/dl.
- At least three weeks must have elapsed from completion of chemotherapy.
- Patient agrees not to use complementary alternative medications (e.g., shark cartilage).
- Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with the policies of the hospital. The only approved consent is appended to this protocol.
Exclusion Criteria:
- Patients with borderline, low grade or low malignant potential tumors are not eligible.
- Patients who are pregnant or lactating.
- Concurrent chemotherapy, radiation therapy or surgery.
- Concurrent, uncontrolled, medical or psychiatric disorders.
- Patients with a known hypersensitivity to interferon.
- Patients with severe cardiovascular disease (i.e. arrhythmias requiring chronic treatment or congestive heart failure) (NYHA classification III or IV).
- Patients who have had interferon within the last 6 months.
- Patients with overt psychosis or mental disability or otherwise incompetent to give informed consent.
- Patients with a known autoimmune disorder.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: PEG-interferon alfa-2b
Patients receive PEG-interferon alfa-2b (PEG IFN-α) subcutaneously (SC) on days 1, 8, 15, and 22.
|
Starting dose 1.0 mg/kg/week given subcutaneously
Andra namn:
Biological/Vaccine: PEG-interferon alfa-2b Dose 1.5 mg/kg/week given subcutaneously EG-Intron
Andra namn:
|
Experimentell: Arm II
Patients receive PEG IFN-α SC (at a higher dose than in arm I) on days 1, 8, 15, and 22.
|
Biological/Vaccine: PEG-interferon alfa-2b Dose 1.25 mg/kg/week given subcutaneously
Andra namn:
|
Experimentell: Arm III
Patients receive PEG IFN-α SC (at a higher dose than in arm II) on days 1, 8, 15, and 22.
|
Starting dose 1.0 mg/kg/week given subcutaneously
Andra namn:
Biological/Vaccine: PEG-interferon alfa-2b Dose 1.5 mg/kg/week given subcutaneously EG-Intron
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Optimal Biologic Dose at 8 weeks
Tidsram: 8 weeks
|
Optimum biologic dose of PEG Intron in patients with platinum-resistant ovarian, fallopian tube or peritoneal cancer whose tumors test positive for IL-8, BFGF, or VEGF.
|
8 weeks
|
Tumor Response
Tidsram: Every 2 -3 cycles (8 - 12 weeks)
|
Each patient tumor response scored as either complete/partial response (CR/PR), stable disease (SD), or failure (F) at 8 weeks after initial treatment.
|
Every 2 -3 cycles (8 - 12 weeks)
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Judith K. Wolf, MD, M.D. Anderson Cancer Center
- Studiestol: Pedro T. Ramirez, MD, M.D. Anderson Cancer Center
- Studiestol: Diane C. Bodurka, MD, M.D. Anderson Cancer Center
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Genitala neoplasmer, hona
- Adnexala sjukdomar
- Äggledarsjukdomar
- Äggledarneoplasmer
- Läkemedels fysiologiska effekter
- Anti-infektionsmedel
- Antivirala medel
- Antineoplastiska medel
- Immunologiska faktorer
- Interferoner
- Interferon-alfa
- Interferon alfa-2
- Peginterferon alfa-2b
Andra studie-ID-nummer
- ID02-115
- P30CA016672 (U.S.S. NIH-anslag/kontrakt)
- P50CA083639 (U.S.S. NIH-anslag/kontrakt)
- MDA-ID-02115 (Annan identifierare: UT MD Anderson Cancer Center)
- CDR0000368964 (Registeridentifierare: NCI PDQ)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Äggstockscancer
-
Ann & Robert H Lurie Children's Hospital of ChicagoOkändCystektomi | Godartade cystor Ovarian | Torsion | Maligna cystor OvarianFörenta staterna
-
Assistance Publique - Hôpitaux de ParisAktiv, inte rekryterandeOkomplicerad Tubo Ovarian AbscessFrankrike
-
Peking University Third HospitalHar inte rekryterat ännuOvarian clear cell carcinoma
-
Dansk FertilitetsklinikOkändKvinnlig infertilitet | Hypogonadism; OvarianDanmark
-
AstraZenecaAvslutadOvarian, Äggledaren, Peritoneal cancer, P53 MutationFörenta staterna, Kanada, Nederländerna
-
University Health Network, TorontoAvslutad
-
M.D. Anderson Cancer CenterGSK Pharma; LixteRekryteringOvarian clear cell carcinomaFörenta staterna
-
National University Hospital, SingaporeOkändOvarian clear cell carcinomaSingapore
-
Tongji HospitalWuhan University; Henan Cancer Hospital; Qilu Hospital of Shandong University och andra samarbetspartnersRekryteringOvarian clear cell carcinomaKina
-
SpringWorks Therapeutics, Inc.Aktiv, inte rekryterandeÄggstockscancer | Ovarian granulosa celltumör | Ovarian Granulosa-Stromal tumörFörenta staterna, Kanada, Polen
Kliniska prövningar på PEG-interferon alfa-2b
-
Brooke Army Medical CenterT.R.U.E. Research FoundationAvslutad
-
Northwestern UniversityNational Cancer Institute (NCI)AvslutadLymfomFörenta staterna
-
Mayo ClinicNational Cancer Institute (NCI)Aktiv, inte rekryterandePrimär myelofibros | Sekundär myelofibrosFörenta staterna
-
Shanghai General Hospital, Shanghai Jiao Tong University...AvslutadUpprepning | Hematologiska neoplasmerKina
-
Merck Sharp & Dohme LLCAvslutad
-
M.D. Anderson Cancer CenterNovartisAvslutadLeukemi, Myeloid, KroniskFörenta staterna
-
NovartisHuman Genome Sciences Inc.AvslutadKronisk hepatit CTaiwan, Tyskland, Grekland, Italien, Spanien, Storbritannien, Frankrike, Kanada, Australien, Indien, Polen, Thailand
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI)AvslutadMelanom (hud)Förenta staterna
-
Mitsubishi Tanabe Pharma CorporationVertex Pharmaceuticals IncorporatedAvslutad
-
M.D. Anderson Cancer CenterSchering-Plough; Eisai Inc.AvslutadMelanomFörenta staterna